Regulatory Roundup: St. Jude Resolves Warning Letter; DePuy Synthes Recall; Syphilis Screening Guidance
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical resolves neuromodulation device facility warning letter; Depuy Synthes craniomaxillofacial distraction system recall tapped as class I; FDA recommends syphilis screening test policies.
You may also be interested in...
Regulatory News In Brief
FDA released a final rule on protections for children in clinical trials and a final guidance on financial disclosures by investigators. More regulatory news.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.